Vera Therapeutics is trading 5.38% down today at $40.16 following a sharp post-approval pullback as investors lock in gains.
- The decline is characterized as a classic "buy the rumor, sell the news" move after the stock rallied in anticipation of the July 7 FDA accelerated approval for TRUTAKNA.
- The weakness is company-specific, occurring even as the broader market trades slightly higher.
- Shares reversed lower on July 10, marking a significant correction from the recent run-up.